Guest View
User: Pass: | become a member


XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations

Courtesy of Benzinga.

XOMA Corporation (Nasdaq: XOMA) today announced it has acquired U.S. rights to the perindopril franchise from Les Laboratoires Servier, XOMA’s partner for its lead product candidate, gevokizumab (formerly XOMA 052). The agreement includes the branded product ACEON® (perindopril erbumine), a currently marketed angiotensin converting enzyme inhibitor, and a portfolio of three fixed-dose combination product candidates where perindopril is combined with other active ingredient(s), such as a calcium channel blocker.

The proprietary form of perindopril in each of the combination products provides patent protection until 2023. XOMA plans to assume commercialization activities for ACEON on January 23, 2012, following the transfer from Servier’s previous licensee.

The Company reaffirmed its guidance that XOMA anticipates that its cash utilization from ongoing activities will be approximately $35 million in 2012.


For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.

Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!




You must be logged in to make a comment.
You can sign up for a membership or get a free SWW trial or log in.

Dashboard

 Sector Performances (Today)

 Thermal Imaging